Aarti Pharmalabs sets Sep 15, 2026 as Record Date for ₹2 Final Dividend for FY26
Aarti Pharmalabs has set September 15, 2026, as the Record Date for its Final Dividend of ₹2.00 per equity share (40%) for FY 2025-26. The dividend payment is subject to shareholder approval at the AGM on September 22, 2026, with payment expected by October 20, 2026.
The dividend announcement directly impacts shareholders by confirming a payout. The amount is moderate, and the record date and AGM provide a clear timeline.
The announcement of a final dividend is generally viewed positively by investors as it represents a return of profits to shareholders.
Aarti Pharmalabs Limited has announced that Tuesday, September 15, 2026, has been fixed as the 'Record Date' for the payment of its Final Dividend for the Financial Year 2025-26.
This final dividend amounts to 40%, which translates to ₹2.00 per Equity Share of ₹5 each. This recommendation was made during the Board Meeting held on May 25, 2026.
The dividend will be disbursed to the shareholders whose names appear in the Company's Register of Members as of the Record Date. This payment is contingent upon the approval of the shareholders at the upcoming Annual General Meeting (AGM), which is scheduled for Tuesday, September 22, 2026. The company has committed to paying the dividend on or before Tuesday, October 20, 2026.
What to do with a filing like this
Aarti Pharmalabs Limited filed this with the NSE as a statutory disclosure, categorised under dividend. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aarti Pharmalabs Limited. Read the original for the full detail.